Merck Reports P-III Trial (KEYNOTE-756) Results of Keytruda for High-Risk, Early-Stage ER+/HER2- Breast Cancer
Shots:
- The P-III trial (KEYNOTE-756) evaluating Merck’s Keytruda (anti-PD-1 therapy) + CT as neoadjuvant treatment in a ratio (1:1) in 1240 patients, followed by adjuvant treatment with Keytruda + endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer
- The trial met the 1EPs of pCR rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen for high-risk, early-stage ER+/HER2- breast cancer. The safety profile was consistent with prior reported studies with no new safety signals
- The trial will continue without changes to evaluate the other dual 1EPs of EFS, based on DMC recommendation. At a prespecified interim analysis conducted by an independent DMC, significant improvement in pCR rate over PBO + CT
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
